Phase 4 HIV and AIDS Trial, Recruiting NCT05266898 Sponsor: Louisiana State University Health Sciences Center in New Orleans Condition: HIV and AIDS
Back to Hiv Aids

Phase 4 HIV and AIDS Trial, Recruiting

NCT05266898
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are HIV-positive
  • People whose immune system is in a stable range, shown by a CD4+ T cell count above 200 cells/ml in a blood test
  • People whose HIV is well-controlled, with a very low amount of virus detected in the blood (fewer than 1,000 copies per mL)
  • People who have been on a stable HIV treatment regimen for at least 3 months
  • People who have never received the Gardasil-9 HPV vaccine and are aged 45 or under, OR people who have records showing they received all 3 doses of either the Gardasil-4 or Gardasil-9 HPV vaccine in the past

Who may not be able to join:

  • People who have a medical reason that would make vaccination unsafe (this applies only to those who have never received the HPV vaccine)
  • People who are currently pregnant
  • People who are currently experiencing an acute (sudden or short-term) illness
  • People who are taking ongoing steroid medication at a dose higher than 0.5mg/kg of prednisone, or an equivalent amount of another steroid
  • People who are taking medications that affect how the immune system works
  • People who have received a blood transfusion or blood products within the past 6 months
  • People who have received any other vaccine within the past month
  • People who are not able to provide written informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Jennifer E Cameron, PhD, Louisiana State University Health Sciences Center

Phone: 504-568-4804

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Louisiana State University Health Sciences Center in New Orleans
Registry
ClinicalTrials.gov
Start date
30 November 2022
Est. completion
1 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

change in serological response to Gardasil-9; serum antibody titers in vaccine-experienced cohort

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov